Slides
Page 1
Company Presentation 2026
Page 2
We create value in Life Science and contribute to improved quality of life 2
Page 3
MedCap Snapshot Q3 2025 3 Revenue, LTM million SEK 1 991 Business Areas Employees & locationsEBITA margin LTM 17% Buy & Build A long-term home for well run Life Science companies Strategy EBITA CAGR 5 years 25% 630 Assistive Tech MedTech Specialty Pharma
Page 4
MedCap | An active investor in Life Science companies 4 Assistive T ech 46% MedTech 33% Specialty Pharma 21% 1 991 MSEK Sales by Business Area Last Twelve Months, Q3 2025 Sweden 45% Nordic 29% Europe 23% RoW 3% Sales by Market
Page 5
Our Model 5 Decentralized & local responsibility Integrity of acquired brands Quick & agile, yet long -term mindset Ambitious organic business plans Sector focus Network of expertise Knowledge sharing Market insight Scalable business areas Merger & Acquisitions Governance – ESG Financing Life Science Entrepreneurship Group Scale
Page 6
MedCap Business Areas 6 Assistive Tech Specialty PharmaMed Tech Cognition, Alarms, Communication Accessibility Mobility Diagnostic ECG Probiotics, Nutrition, Packaging Components for medical imaging Ultra clean air for infection control Pharma CDMO Orthopedic aids Simplifying life for individuals with special needs Digitalizing work-flow Contract manufacturing Cost effective air quality in ORCarbon fiber CDMO Nordic Sales, Pharma portfolio, Non-license Sterile & non-sterile liquid pharma production Patient handling
Page 7
Our business 7 Payor Understanding the eco-systems Prescriber Sales & Marketing End-user People & Management Regulation Active ownershipSolid markets Healthcare providers Distribution OfferingProduct Development Business objectives Performance management Bolt-on acquisitions Non-cyclical Demographic drivers Market nisches Market share potential
Page 8
How we grow our group 8 Organic Growth Plans in Subsidiaries A Good Home for Life Science Companies Add-on or Adjascent Acquisitions Decentral Business Ownership and Group Support New Platforms Companies in our subsidiaries’ network Active industry participation and search Succession or next step situations Structured sales processes
Page 9
Investment strategy 9 Life Science Assistive | MedTech | Pharma Europe Add-ons globally Long-term Buy & Build | No exit horizon Scope What we look for Small / Mid-size Businesses Sales <50 mEUR Majority Owner 51-100% Ownership PEOPLE PROFITABILITY Product / Software / Know-how Clear value proposition Market fundamentals ESG Solid underlying business Commercially proven Self-funded and Cost control Value creation journey Scalable business M&A possibilities Innovative Entrepreneurial management
Page 10
20 years of acquisitions 10 20062005 2008 20092007 Quickels, Acquisition Dunmedic, Add-on (IM-Medico) Unimedic, Acquisition 2010 2019 IM-Medico, Acquisition VC-portfolio, Exit IM-Medico, Sale of property GEWA (Abilia), Acquisition Handitek, Add-on (GEWA – changed name to Abilia) Falck Igel, Add-on (Abilia) Abilia, Refinancing (30 MSEK) 2011 2012 2013 2014 2015 2016 2017 2018 Unimedic, Sale of product (D-droppar) IM-Medico, Exit Ergobe, Add-on (Unimedic) Toby Churchill, Add- on (Abilia) Pharmadone, Add-on (Unimedic) Cross Pharma, Add- on (Unimedic) ForGetMeNot, Add- on (Abilia) Miwana, Add-on (Unimedic) Cardiolex, Add-on (Quickels) Inpac, Acquisition Emfit, Add-on (Abilia) Scandinavian Nutrients, Add-on (Inpac AirContainer) Strässle, Add-on (Cardiolex) 2020 Comai, Add-on (Abilia) Amedtec, Add-on (Cardiolex) Somna, Add-on (Abilia) Multi-Ply Acquisition 1 5 2 3 4 6 7 8 9 11 12 13 10 18 19 14 15 16 17 21 22 23 20 26 24 25 27 2021 2022 Cognita, Add-on (Abilia) D-Drop, Product divestment (Unimedic) AdderaCare, announced public buyout incl. five add-ons (Abilia / Assist.T) 28 29 30 2023 Toul Meditech & SurgiCube, Acquisition Swedelift, Add-on (Assistive Tech / Trident) 31 32 2024 Kompany, Add- on (Abilia) Picomed / Alert-IT, Add-on (Abilia / Assistive Tech) 33 34 2025 DanRehab, Acquisition XGX Pharma, Add-on (Unimedic) Nightwatch, Add-on (Abilia) 35 36 37
Page 11
Sales and EBITA rolling 12 months by quarter 11 801 817 834 858 885 916 956 1,007 1,046 1,111 1,229 1,331 1,454 1,587 1,669 1,740 1,789 1,807 1,839 1,903 1,991 103 111 119 127 133 145 160 167 178 187 203 232 260 291 319 328 331 306 302 318 340 0 50 100 150 200 250 300 350 400 450 500 0 100 200 300 400 500 600 700 800 900 1,000 1,100 1,200 1,300 1,400 1,500 1,600 1,700 1,800 1,900 2,000 2,100 2,200 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Net sales EBITA R12 MSEK (Net sales) MSEK (EBITA) Sales CAGR: 19% EBITA CAGR: 26% Excluding one-time effects
Page 12
Financial Targets 12 Annual EBITA Growth >15% Net debt / EBITDA <3x Return on Equity >20% -1 -0.5 0 0.5 1 1.5 2 2.5 3 2020 2021 2022 2023 2024 2025 0 50 100 150 200 250 300 350 400 2020 2021 2022 2023 2024 2025 [MSEK] Compounded Average Growth Rate 0% 5% 10% 15% 20% 25% LTM LTM